Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 1
1960 1
1962 1
1963 9
1964 7
1965 7
1966 1
1969 3
1970 1
1971 4
1972 3
1973 4
1974 13
1975 28
1976 26
1977 42
1978 32
1979 31
1980 73
1981 103
1982 144
1983 162
1984 200
1985 224
1986 248
1987 217
1988 360
1989 453
1990 455
1991 515
1992 614
1993 622
1994 670
1995 784
1996 848
1997 866
1998 989
1999 1058
2000 1187
2001 1311
2002 1329
2003 1443
2004 1638
2005 1765
2006 1957
2007 2106
2008 2349
2009 2457
2010 2529
2011 2617
2012 2757
2013 2814
2014 3113
2015 3223
2016 3086
2017 3087
2018 3208
2019 3449
2020 3918
2021 4048
2022 3524
2023 3446
2024 3867
2025 3098
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71,030 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for tumor ag
Search for Tudor AG instead (2 results)
Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing.
Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, Nikfar S, Tsatsakis A, Abdollahi M. Sadeghi HM, et al. Int J Mol Sci. 2022 Jan 6;23(2):583. doi: 10.3390/ijms23020583. Int J Mol Sci. 2022. PMID: 35054768 Free PMC article. Review.
Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, glucose-like peptide-1 receptor agonists, mucolytic agents, and some supplement …
Medications, including 3-hydroxy-3-methyl-3-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, thiazolidinediones, sodium-glucose cotranspo …
Pancreatic Cysts.
Gonda TA, Cahen DL, Farrell JJ. Gonda TA, et al. N Engl J Med. 2024 Sep 5;391(9):832-843. doi: 10.1056/NEJMra2309041. N Engl J Med. 2024. PMID: 39231345 Review. No abstract available.
Hirsutism in Women.
Matheson E, Bain J. Matheson E, et al. Am Fam Physician. 2019 Aug 1;100(3):168-175. Am Fam Physician. 2019. PMID: 31361105 Free article. Review.
Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumors, medications, hyperprolactinemia, thyroid disorders, and Cushing syndrome. Women with an abnormal hirsutism score based on the Ferriman-Gallwey scoring sys …
Less common causes include idiopathic hirsutism, nonclassic congenital adrenal hyperplasia, androgen-secreting tumors, medications, h …
Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease.
Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, Michos ED. Guan C, et al. Fertil Steril. 2022 May;117(5):924-935. doi: 10.1016/j.fertnstert.2022.03.009. Fertil Steril. 2022. PMID: 35512976 Free article. Review.
Other medications, such as metformin and glucagon-like peptide-1 receptor agonists, also may be useful in reducing CVD risk in insulin-resistant populations. Additional research is needed to determine the best pathways to mitigate PCOS-associated CVD risk....
Other medications, such as metformin and glucagon-like peptide-1 receptor agonists, also may be useful in reducing CVD risk in insuli …
Racial and ethnic disparities in polycystic ovary syndrome.
VanHise K, Wang ET, Norris K, Azziz R, Pisarska MD, Chan JL. VanHise K, et al. Fertil Steril. 2023 Mar;119(3):348-354. doi: 10.1016/j.fertnstert.2023.01.031. Epub 2023 Jan 23. Fertil Steril. 2023. PMID: 36702345 Free PMC article. Review.
Aryl hydrocarbon receptor ligands in cancer: friend and foe.
Murray IA, Patterson AD, Perdew GH. Murray IA, et al. Nat Rev Cancer. 2014 Dec;14(12):801-14. doi: 10.1038/nrc3846. Nat Rev Cancer. 2014. PMID: 25568920 Free PMC article. Review.
Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically …
Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell …
The FIGO ovulatory disorders classification system.
Munro MG, Balen AH, Cho S, Critchley HOD, Díaz I, Ferriani R, Henry L, Mocanu E, van der Spuy ZM; FIGO Committee on Menstrual Disorders and Related Health Impacts, and FIGO Committee on Reproductive Medicine, Endocrinology, and Infertility. Munro MG, et al. Int J Gynaecol Obstet. 2022 Oct;159(1):1-20. doi: 10.1002/ijgo.14331. Epub 2022 Aug 19. Int J Gynaecol Obstet. 2022. PMID: 35983674 Free PMC article.
IL-27 elicits a cytotoxic CD8(+) T cell program to enforce tumour control.
Bréart B, Williams K, Krimm S, Wong T, Kayser BD, Wang L, Cheng E, Cruz Tleugabulova M, Bouziat R, Lu T, Yuen K, Firmino NS, Bravo DD, Roels J, Bhakta A, Bevers J 3rd, Lehoux I, Gutierrez A, Chestnut Y, Klementowicz JE, Arenzana TL, Akhmetzyanova I, Dixon E, Chen M, Tasneem K, Yadav R, Koeppen H, Oh SA, Delamarre L, Huang H, Lim SA, Nakamura G, Wang J, Gao C, Corpuz R, Müller S, West NR. Bréart B, et al. Nature. 2025 Mar;639(8055):746-753. doi: 10.1038/s41586-024-08510-w. Epub 2025 Feb 5. Nature. 2025. PMID: 39910298
Here we show that expression of a CTL signature is strongly associated with IL27 expression in human and mouse tumours. In mice, IL-27 acts directly on tumour-specific CTLs to promote their persistence and effector function in the tumour microenvironment. Mor …
Here we show that expression of a CTL signature is strongly associated with IL27 expression in human and mouse tumours. In mice, IL-2 …
Targeting TRAIL.
Ion GND, Nitulescu GM, Popescu CI. Ion GND, et al. Bioorg Med Chem Lett. 2019 Sep 15;29(18):2527-2534. doi: 10.1016/j.bmcl.2019.07.053. Epub 2019 Jul 30. Bioorg Med Chem Lett. 2019. PMID: 31383590 Review.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, has been investigated in the past decade for its promising anticancer activity due to its ability to selectively induce apoptosis in tumoral cells by binding to TRAIL receptors (TR …
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, has been investigated in the past decade for it …
71,030 results
You have reached the last available page of results. Please see the User Guide for more information.